New Drug Target Identified for Treatment of Type 2 Diabetes

A mitochondrial protein complex has been identified by researchers at Metabolic Solutions Development Company (MSDC) through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes. The mitochondrial protein complex is being referred to as the mitochondrial Target of Thiazolidinediones (TZDs), or mTOT™.

Read more...

First in Class mTOT Modulator Meets Phase 2b Study Endpoints

In a recently completed Phase 2b study, MSDC-0160, a novel once-a-day oral insulin sensitizer and a prototype first in a new class of therapeutic agents called mTOT Modulators™, which are being developed by researchers at Metabolic Solutions Development Company (MSDC), met the primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and significantly reduced hemoglobin A1c (HbA1c).

Read more...